Tesamorelin: What It Is, How It Works, and Who It May Help

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that signals the pituitary gland to release a person's own growth hormone in natural pulses. It is FDA-approved under the brand name Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy, and it is studied off-label for visceral belly fat and fatty liver. It is given as a once-daily subcutaneous injection under clinician supervision [1][3].

What is tesamorelin?

Tesamorelin (international nonproprietary name) is a 44-amino-acid synthetic version of human GHRH. It was developed by Theratechnologies and approved by the U.S. FDA in 2010 under the brand name Egrifta (later reformulated as Egrifta SV and Egrifta WR) [1][3].

Brand name (Egrifta) and drug class

Egrifta is the only FDA-approved tesamorelin product. Tesamorelin is also available as a compounded peptide through some licensed 503A pharmacies; compounded versions are not FDA-approved and have not been independently reviewed by the FDA for safety, efficacy, or quality [6].

How GHRH analogs differ from synthetic HGH

Injected synthetic human growth hormone (HGH, somatropin) replaces growth hormone directly, often producing steady, non-physiologic levels. Tesamorelin works one step upstream: it tells the pituitary to release the body's own growth hormone in the normal pulsing rhythm. This preserves negative feedback through somatostatin and IGF-1, which may reduce the risk of supraphysiologic spikes seen with direct HGH use [4].

How does tesamorelin work in the body?

Tesamorelin binds to GHRH receptors on the anterior pituitary, stimulating pulsatile release of growth hormone (GH). GH then signals the liver and other tissues to produce insulin-like growth factor 1 (IGF-1), which mediates many of GH's downstream effects on body composition [4].

The GHRH-pituitary-IGF-1 pathway

After a bedtime injection, tesamorelin produces a short-lived spike in GH that mimics natural nighttime pulses. Over weeks, IGF-1 rises into the upper-normal range in most patients. Clinicians monitor IGF-1 to keep it within the age-appropriate reference range [3][6].

Why it targets visceral (deep belly) fat

Growth hormone is lipolytic — it activates hormone-sensitive lipase, which breaks down stored triglycerides, especially in visceral adipose tissue (VAT), the deep fat surrounding abdominal organs. VAT is more GH-sensitive than subcutaneous fat, which helps explain why tesamorelin preferentially shrinks deep belly fat in trials [4].

What is tesamorelin approved for, and what is off-label?

FDA-approved use: HIV-associated lipodystrophy

The only FDA-approved indication for tesamorelin is to reduce excess abdominal fat in adults with HIV-associated lipodystrophy — a body-fat redistribution syndrome linked to long-term antiretroviral therapy. Approval was based on two Phase 3 trials showing roughly 15% reduction in VAT versus placebo over 26 weeks [1][4].

Off-label use for visceral fat and body composition

Tesamorelin is being studied for visceral obesity in HIV-negative adults, nonalcoholic fatty liver disease (NAFLD/hepatic steatosis), and age-related body composition changes. These uses are off-label, meaning a clinician may prescribe it based on individual judgment, but the FDA has not reviewed or endorsed these indications [4].

Is tesamorelin similar to Ozempic or other GLP-1s?

No. Tesamorelin and GLP-1 medications like semaglutide (Ozempic, Wegovy, and compounded semaglutide via 503A pharmacies) and tirzepatide (Mounjaro, Zepbound) work through completely different pathways and address different problems.

Different mechanism, different goal

GLP-1 receptor agonists slow stomach emptying, increase satiety, and reduce overall calorie intake, producing broad weight loss across both fat and lean mass [7]. Tesamorelin does not suppress appetite. Instead, it shifts body composition by mobilizing visceral fat through the GH-IGF-1 axis, with little change in total body weight in most trials [4].

When patients consider one vs. the other

GLP-1s are studied and approved for general weight loss and type 2 diabetes. Tesamorelin is studied for deep belly fat and metabolic markers when total weight loss is not the goal. Some clinicians consider them complementary rather than interchangeable, though combination use is not well studied. For more on GLP-1 differences, see the semaglutide vs. tirzepatide comparison.

What does the evidence show about tesamorelin and belly fat?

Visceral adipose tissue reduction

In pooled Phase 3 data of adults with HIV-associated lipodystrophy, tesamorelin reduced VAT by about 15% over 26 weeks compared with a small increase in placebo. Waist circumference and triglycerides also improved. Benefits reversed within 6 months of stopping the drug, suggesting continued use is needed to maintain effects [1][4].

Effects on liver fat and lean muscle

A randomized trial in people with HIV and NAFLD found tesamorelin reduced liver fat by roughly one-third and prevented progression of liver fibrosis over 12 months [4]. Lean body mass tends to stay stable or slightly increase, in contrast to the lean-mass loss often seen with calorie-restriction-driven weight loss.

How is tesamorelin dosed and injected?

The following is educational and not a dosing instruction. Your clinician will set a regimen for you.

Typical dose and timing

The FDA-approved Egrifta regimen is a once-daily subcutaneous injection in the abdomen, typically administered at bedtime to align with the body's natural nighttime GH pulse [3][6].

Injection sites and rotation

Injections are given subcutaneously in the abdomen, rotating sites to reduce lipohypertrophy (lumpy fat tissue) and bruising. Patients are taught to avoid scars, the navel, and any areas of active skin irritation [3][6].

Reconstitution and storage basics

Tesamorelin comes as a powder that must be reconstituted with sterile water before each dose. Once mixed, it is used immediately. Unmixed vials are stored refrigerated. Your pharmacist or clinician will walk you through the exact steps [3][6].

What are the side effects and risks?

Common side effects

The most frequently reported side effects in trials and post-marketing data include injection-site reactions (redness, itching, bruising), joint pain (arthralgia), muscle aches, swelling in the hands and feet (peripheral edema), and tingling or numbness in the limbs [3][6].

Serious risks: blood sugar, IGF-1, and pregnancy

Tesamorelin can raise blood glucose and hemoglobin A1c, particularly in people with prediabetes or type 2 diabetes. It can also push IGF-1 above the normal range, which is a theoretical concern for cancer risk. It is contraindicated in pregnancy and in people with active malignancy, disrupted hypothalamic-pituitary axis, or known hypersensitivity to the drug [3][6].

Who should not take tesamorelin

• People who are pregnant, trying to become pregnant, or breastfeeding
• People with active cancer or a history of certain cancers
• People with pituitary disease, hypopituitarism, or recent pituitary surgery
• People with uncontrolled diabetes or very high IGF-1
• People with a known allergy to tesamorelin or mannitol

What should you avoid while taking tesamorelin?

Late-night meals and alcohol

Because tesamorelin is dosed at bedtime, eating a large, carbohydrate-heavy meal or drinking alcohol close to the injection can blunt the natural GH pulse and may dampen the drug's effect. Many clinicians suggest a 2-3 hour fasting window before injection, though this is practice-based rather than label-required [5].

Drug and condition interactions

Tesamorelin can interact with corticosteroids (which may need dose adjustment), insulin, and oral diabetes medications. It has not been well studied with other GH-axis peptides, GLP-1s, or hormone replacement therapy [3][6].

Skipping recommended labs

Most clinicians check IGF-1, fasting glucose, and hemoglobin A1c at baseline and every 3-6 months. Skipping these labs makes it impossible to catch the most important risks — rising IGF-1 and worsening glucose — before they become a problem [6].

How does tesamorelin compare with other peptides like ipamorelin or CJC-1295?

Tesamorelin, ipamorelin, and CJC-1295 all influence the GH axis but act at different receptors and produce different patterns of release. The table below summarizes how they are commonly described in the peptide literature and compounding practice.

What peptides stack well with tesamorelin?

In clinical practice and the published peptide literature, GH-axis peptides are sometimes combined to target complementary mechanisms. Combinations are not Chia-recommended protocols; combination dosing has not been studied in large trials, and any stack should be supervised by a licensed clinician.

• Tesamorelin + ipamorelin: GHRH-driven release plus ghrelin-receptor-driven release in theory amplifies the natural GH pulse. The safety caveat is overlapping fluid retention, joint pain, and IGF-1 elevation, with no large combination trials.
• Tesamorelin + BPC-157 (in compounding practice): a GH-axis peptide paired with a peptide studied for tissue repair. The caveat is that BPC-157 is not FDA-approved and is currently under FDA review.
• Tesamorelin + CJC-1295/ipamorelin: rarely used together because they hit overlapping receptors. Combined use risks excessive IGF-1 elevation and is not commonly recommended.

How do you get tesamorelin legally and safely?

Brand Egrifta vs. compounded tesamorelin from a 503A pharmacy

Egrifta (and Egrifta SV/WR) is the only FDA-approved tesamorelin and is dispensed by specialty pharmacies. Some licensed 503A compounding pharmacies also prepare tesamorelin to a clinician's prescription; compounded tesamorelin is not FDA-approved and is not reviewed by the FDA for safety, efficacy, or potency, but it is a legal pathway when prescribed by a licensed clinician for an individual patient.

Getting evaluated by a licensed clinician

Because of the IGF-1, glucose, and contraindication issues above, tesamorelin requires a clinical evaluation. Expect a review of your medical history, baseline labs (IGF-1, A1c, fasting glucose, often a lipid panel), and a discussion of goals. Many people exploring tesamorelin also explore other longevity peptides — the longevity peptides overview goes deeper on the category.

Where Chia fits in

Chia is one of several telehealth options that connect patients to licensed clinicians who can evaluate eligibility for tesamorelin and, when appropriate, prescribe brand or compounded formulations through partnered 503A pharmacies. The right choice depends on your goals, history, and labs, not on any one provider.

Frequently asked questions about tesamorelin

Keep reading

Longevity Peptides

Tesamorelin: How It Works, Uses, and Side Effects

Peptides

Peptide Injections: What They Are, How They Work, and What to Expect

Weight Loss

Peptides for Weight Loss: How They Work and What to Know